• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    9/5/23 5:31:53 PM ET
    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Akanda (NASDAQ:AKAN) shares increased by 13.5% to $0.63 during Tuesday's after-market session. Trading volume for this security closed at 668.1K, accounting for 276.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million.
    • VolitionRX (AMEX:VNRX) shares moved upwards by 11.99% to $1.4. The company's market cap stands at $109.3 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 10.46% to $0.95. The market value of their outstanding shares is at $11.1 million.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 8.19% to $0.55. The market value of their outstanding shares is at $83.7 million.
    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 7.49% to $0.04.
    • AIM ImmunoTech (AMEX:AIM) stock increased by 6.23% to $0.64. The company's market cap stands at $31.3 million.

    Losers

    • XBiotech (NASDAQ:XBIT) stock fell 6.7% to $4.49 during Tuesday's after-market session. The market value of their outstanding shares is at $136.6 million.
    • Carmell Therapeutics (NASDAQ:CTCX) stock declined by 5.61% to $4.04. The company's market cap stands at $93.2 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock fell 5.38% to $0.27. At the close, Novo Integrated Sciences's trading volume reached 20.9 million shares. This is 74.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $43.2 million.
    • EyePoint Pharmaceuticals (NASDAQ:EYPT) stock declined by 5.09% to $8.96. The market value of their outstanding shares is at $313.4 million.
    • Orgenesis (NASDAQ:ORGS) stock fell 5.08% to $0.71. The company's market cap stands at $21.6 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares decreased by 4.96% to $0.38. Today's trading volume for this security ended up closing at 243.6K shares, which is 86.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $CTCX
    $EYPT
    $HLTH

    CompanyDatePrice TargetRatingAnalyst
    EyePoint Pharmaceuticals Inc.
    $EYPT
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    VolitionRX Limited
    $VNRX
    4/8/2025$2.50Buy
    H.C. Wainwright
    EyePoint Pharmaceuticals Inc.
    $EYPT
    1/7/2025$33.00Buy
    Citigroup
    EyePoint Pharmaceuticals Inc.
    $EYPT
    10/16/2024Sector Outperform
    Scotiabank
    EyePoint Pharmaceuticals Inc.
    $EYPT
    8/28/2024$15.00Buy
    Jefferies
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Yield10 Bioscience Inc.
    $YTEN
    2/8/2024Buy → Hold
    Lake Street
    EyePoint Pharmaceuticals Inc.
    $EYPT
    1/22/2024$35.00Overweight
    JP Morgan
    More analyst ratings

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Volition Sponsors Upcoming GenomeWeb Webinar

    HENDERSON, Nev., Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wednesday, October 8 (details can be found below). Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition, said: "This webinar will showcase our Nu.Q® Discover service and how it provides drug developers and scientists a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies." Details of the Webinar: Beyond t

    10/2/25 8:45:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akanda Discusses Altán Redes $7 Billion Project

    Unprecedented Scale and Investment to Connect MexicoToronto, Ontario--(Newsfile Corp. - October 1, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), expands on the size and scale of Mexico's telecommunications infrastructure project, under the Red Compartida initiative. Altán Redes is undertaking one of the largest telecommunications undertakings in Mexico's history. The mission: to close the digital divide by building a wholesale LTE/4G (and progressively 5G-ready) network that will reach the vast majority of the Mexican population. As a preferred contractor of Altán Redes, every tower that FTF builds is expected

    10/1/25 8:00:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Akanda Among the Leaders of Deployment in Mexico's Largest Telecommunication Infrastructure Project

    Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") is pleased to report on the progress of its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"). FTF, a leader in telecommunications infrastructure in Mexico, today announced its continued commitment to increase data connectivity as a preferred contractor in Mexico's largest telecommunications infrastructure public / private project, managed by Altan Redes and CFE Telecomunicaciones. With 30 cellular towers already deployed and generating revenue throughout Mexico, FTF brings proven expertise and operational capacity to the project. The Company expects to play a key role in

    9/30/25 4:15:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    SEC Filings

    View All

    XBiotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - XBiotech Inc. (0001626878) (Filer)

    10/3/25 11:15:44 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Akanda Corp.

    424B3 - AKANDA CORP. (0001888014) (Filer)

    10/1/25 1:35:41 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Akanda Corp.

    424B3 - AKANDA CORP. (0001888014) (Filer)

    10/1/25 8:00:49 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $9,885 worth of shares (15,000 units at $0.66), increasing direct ownership by 0.57% to 2,624,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    9/15/25 9:00:07 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $50,000 worth of shares (78,125 units at $0.64), increasing direct ownership by 9% to 966,814 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/6/25 9:00:21 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $50,000 worth of shares (78,125 units at $0.64), increasing direct ownership by 3% to 2,609,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/6/25 9:00:10 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO - Volition Veterinary Butera Salvatore Thomas covered exercise/tax liability with 5,230 shares, decreasing direct ownership by 2% to 332,285 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    9/30/25 4:02:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Secretary Rootsaert Rodney Gerard covered exercise/tax liability with 4,158 shares, decreasing direct ownership by 3% to 145,075 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    9/30/25 4:02:03 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Scientific Officer Micallef Jacob Vincent covered exercise/tax liability with 5,568 shares, decreasing direct ownership by 1% to 398,939 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    9/30/25 4:01:49 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Leadership Updates

    Live Leadership Updates

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

    OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an

    2/26/25 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Volition Issues Business Review 2024

    HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

    1/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, August 15, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34

    8/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti

    8/6/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

    WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the

    7/30/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care